gedatolisib + palbociclib or ribociclib + fulvestrant

Gedatolisib is an investigational small molecule that acts as a potent and reversible dual inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), targeting all class I PI3K isoforms as well as mTOR complex 1 and 2. It is being studied primarily for the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. Palbociclib and ribociclib are oral small molecule inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6), which block cell cycle progression in cancer cells. Fulvestrant is a selective estrogen receptor degrader used in endocrine therapy for HR+ breast cancer. The combination regimens—gedatolisib plus palbociclib or ribociclib plus fulvestrant—are under investigation to improve tumor control by simultaneously inhibiting the PI3K/mTOR pathway (gedatolisib), cell cycle progression (palbociclib/ribociclib), and estrogen signaling (fulvestrant) in patients with advanced HR+, HER2-negative breast cancer[1][3][4][5][6].

Brand names

IBRANCEKisqali